fbpx

ALK-Abelló A/S

alk

ALK-Abelló A/S is an international pharmaceutical company devoted to improve the lives of people with allergies by developing pharmaceuticals products that target the cause of allergy.

ALK-Abelló A/S is the world leader in allergy vaccination (immunotherapy) – a unique treatment including a protective immune response that reduces and potentially halts the allergic reaction.

For further information: www.alk.net

Lundbeckfonden

News

Eske Willerslev receives prestigious Norwegian science prize for his Lundbeck Foundation research on brain disorders
22. January 2021
Science Programme Director (Open Neuroplatform)
18. January 2021
Scientific Programme Director (Talent programs)
15. January 2021